Professor, Family and Community Medicine, UC, Davis School of Medicine
Family Medicine
Dr. Joy Melnikow, MD
|
|
Give Review
Melnikow works in the field of Family Medicine. He attended University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is one of the top medical schools in the US. University of California San Francisco School of Medicine has a rank of 3 in research and a 3 in primary care He received awards:"CMS Meaningful Use Stage 1 Certification". Doctor Joy Melnikow, MD is a published doctor. He has 31 publications published. The most current publication "Calcium supplementation during pregnancy." He is registered with Medicare and accepts Medicare payments.
Publications
- Patient Admission Preferences and Perceptions.
- Dose Escalation During the First Year of Long-Term Opioid Therapy for Chronic Pain.
- Variability of ICU use in adult patients with minor traumatic intracranial hemorrhage.
- Counterpoint: Randomized Trials Provide the Strongest Evidence for Clinical Guidelines: The US Preventive Services Task Force and Prostate Cancer Screening.
- Why quantile regression makes good sense for analyzing economic outcomes in medical research.
- Can automated alerts within computerized physician order entry improve compliance with laboratory practice guidelines for ordering Pap tests?
- Program-specific cost-effectiveness analysis: breast cancer screening policies for a safety-net program.
- Translation of health surveys using mixed methods.
- Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness.
- Mammography screening for breast cancer: recommendation of the U.S. Preventive Services Task Force.
- ACP Journal Club. Review: Tamoxifen, raloxifene, and tibolone prevent primary invasive breast cancer but increase risk for adverse outcomes.
- Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study.
- Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review.
- Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
- Review: vaccines against human papillomavirus prevent cervical cancer precursors in young women for at least 3 years.
- Do personal and societal preferences differ by socio-demographic group?
- Chemoprevention: drug pricing and mortality: the case of tamoxifen.
- Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.
- Human papillomavirus triage of atypical squamous cells of undetermined significance: cost-effective, but at what cost?
- Recruitment strategies for minority participation: challenges and cost lessons from the POWER interview.
- "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction.
- Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
- Medical adherence research: time for a change in direction?
- Networked for change? Identifying obstetric opinion leaders and assessing their opinions on caesarean delivery.
- Risk of cervical cancer associated with extending the interval between cervical-cancer screenings.
- Conservative versus aggressive follow up of mildly abnormal Pap smears: testing for process utility.
- Management of the low-grade abnormal Pap smear: What are women's preferences?
- Reporting number needed to treat and absolute risk reduction in randomized controlled trials.
- Calcium supplementation during pregnancy.
- Economic Evaluation of Telemedicine for Patients in ICUs.
Schools
University Of California San Francisco School Of Medicine
University Mass
Doctors Specialties
- Family Medicine
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Guided Access HMO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Select PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Delta Health System
- First Health (Coventry Health Care) PPO
- Blue & Gold HMO
- Covered California - Bronze PPO
- Employer Group HMO
- Health Net PPO
- Individual and Family PPO
- Medicare MCR
- Molina
- MultiPlan PPO
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
- Western Health Advantage
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Massachusetts -
University of California San Francisco School of Medicine
Hospital
-
University of California, Davis Medical Center
Drug Facts
| NPI NUMBER | 1679558688 | |
| NPPES Provider LastName | MELNIKOW | |
| NPPES Provider FirstName | JOY | |
| NPPES Provider ZIPCode | 958172307 | |
| NPPES Provider State | CA | |
| Specialty Description | Family Practice | |
| Total Claim Count | 1406.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 62.0 | |
| Percent Opioid Claims | 4.41 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1679558688 |
| Last Name Of The Provider | MELNIKOW |
| First Name Of The Provider | JOY |
| View All |
Similar Doctors
|
|
Dr. John K. Doolittle, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bella Agrawal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jin Tang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaesu Han, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ashkan Javaheri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David W. Lin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin M. Barnes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Annalyse A. Feldman, DO |
|
|
Dr. Stanley R. Gambrill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Megan M. Ash, MD |
|
|
Dr. Viola W. Chu, MD |
|
|
Dr. Dr Sandra I. Odiase, DNP |